CoChat

A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes

Sherratt, Samuel C.R., Libby, Peter, Bhatt, Deepak L., Mason, R. Preston · 2022 · Prostaglandins, Leukotrienes and Essential Fatty Acids
Cited by 43

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.plefa.2022.102450

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 133

  1. Bhatt, 2020, A Revolution in Omega-3 Fatty Acid Research∗, Journal of the American College of Cardiology, 76, 2098, 10.1016/j.jacc.2020.09.005 · DOI
  2. Mason, 2022, Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction, Metabolism - Clinical and Experimental, 130
  3. Budoff, 2020, Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial, European Heart Journal, 41, 3925, 10.1093/eurheartj/ehaa652 · DOI · Paper page
  4. Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, The Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
  5. Watanabe, 2017, A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins, Journal of Cardiology, 70, 537, 10.1016/j.jjcc.2017.07.007 · DOI · Paper page
  6. Alfaddagh, 2017, Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial, J Am Heart Assoc, 6, 10.1161/JAHA.117.006981 · DOI · Paper page
  7. Nicholls, 2020, Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial, JAMA, 324, 2268, 10.1001/jama.2020.22258 · DOI · Paper page
  8. Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl. Reply, N Engl J Med, 380, 1678, 10.1056/NEJMoa1812792 · DOI · Paper page
  9. Pisaniello, 2020, Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events, European Medical Journal, 5, 29
  10. Aung, 2018, Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals, JAMA Cardiology, 3, 225, 10.1001/jamacardio.2017.5205 · DOI · Paper page
  11. Mason, 2021, Is there a role for omega-3 fatty acids in cardiovascular disease risk reduction?, eClinicalMedicine, 39
  12. Davidson, 2014, Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST), Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1298, 10.1161/ATVBAHA.113.302926 · DOI · Paper page
  13. 2022, Kowa Research Institute I. Kowa to discontine K-877 (pemafibrate) "PROMINENT" cardiovascular outcomes study, Cision PR Newswire
  14. Kita, 2020, Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study, Journal of the American Heart Association, 9, 10.1161/JAHA.119.015593 · DOI · Paper page
  15. Motoyama, 2021, Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology - A Serial Computed Tomography Angiography Study, Circ J
  16. Nakajima, 2011, Orally Administered Eicosapentaenoic Acid Induces Rapid Regression of Atherosclerosis Via Modulating the Phenotype of Dendritic Cells in LDL Receptor-Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 1963, 10.1161/ATVBAHA.111.229443 · DOI · Paper page
  17. Sato, 2019, Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques, Arterioscler Thromb Vasc Biol, 39, 1802, 10.1161/ATVBAHA.119.313093 · DOI
  18. Williams, 2020, Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction, Circulation, 141, 1452, 10.1161/CIRCULATIONAHA.119.044720 · DOI · Paper page
  19. Cawood, 2010, Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability, Atherosclerosis, 212, 252, 10.1016/j.atherosclerosis.2010.05.022 · DOI · Paper page
  20. Sawazaki, 1989, Comparison of the increment in plasma eicosapentaenoate concentrations by fish oil intake between young and middle-aged volunteers, J Nutr Sci Vitaminol (Tokyo), 35, 349, 10.3177/jnsv.35.349 · doi:10.3177/jnsv.35.349
  21. Subbaiah, 1993, Incorporation of dietary n-3 fatty acids into molecular species of phosphatidyl choline and cholesteryl ester in normal human plasma, American Journal of Clinical Nutrition, 58, 360, 10.1093/ajcn/58.3.360 · DOI
  22. Jacobs, 2021, EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol, Biophysical Journal, 120, 2317, 10.1016/j.bpj.2021.04.009 · DOI · Paper page
  23. Soni, 2008, Docosahexaenoic acid enhances segregation of lipids between: 2H-NMR study, Biophys J, 95, 203, 10.1529/biophysj.107.123612 · DOI · Paper page
  24. Querques, 2011, Retina and omega-3, J Nutr Metab, 2011, 10.1155/2011/748361 · DOI
  25. Innis, 2007, Dietary (n-3) fatty acids and brain development, J Nutr, 137, 855, 10.1093/jn/137.4.855 · DOI · Paper page
  26. Uauy, 2006, Nutrition in brain development and aging: role of essential fatty acids, Nutr Rev, 64, 10.1301/nr.2006.may.S24-S33 · DOI · Paper page
  27. Chang, 1995, Attenuation of channel kinetics and conductance by cholesterol: an interpretation using structural stress as a unifying concept, J Membr Biol, 143, 51, 10.1007/BF00232523 · DOI
  28. Heijman, 2014, Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression, Circulation Research, 114, 1483, 10.1161/CIRCRESAHA.114.302226 · DOI · Paper page
  29. Maixent, 2002, Remodeling of Na,K-ATPase, and membrane fluidity after atrial fibrillation in sheep, J Recept Signal Transduct Res, 22, 201, 10.1081/RRS-120014596 · DOI
  30. Doi, 2014, Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study, Int J Cardiol, 176, 577, 10.1016/j.ijcard.2014.08.055 · DOI
  31. Myhre, 2021, Changes in EPA and DHA during supplementation with omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial, European Heart Journal, 42
  32. Witztum, 1994, The oxidation hypothesis of atherosclerosis, Lancet, 344, 793, 10.1016/S0140-6736(94)92346-9 · DOI · Paper page
  33. Chisolm, 2000, The oxidative modification hypothesis of atherogenesis: an overview, Free Radic Biol Med, 28, 1815, 10.1016/S0891-5849(00)00344-0 · DOI · Paper page
  34. Ehara, 2001, Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes, Circulation, 103, 1955, 10.1161/01.CIR.103.15.1955 · DOI · Paper page
  35. Walter, 2008, Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study, J Am Coll Cardiol, 51, 1196, 10.1016/j.jacc.2007.11.051 · DOI
  36. Walter, 2004, Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study, J Am Coll Cardiol, 44, 1996, 10.1016/j.jacc.2004.08.029 · DOI · Paper page
  37. Holvoet, 2004, The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort, Diabetes, 53, 1068, 10.2337/diabetes.53.4.1068 · DOI · Paper page
  38. Mason, 1997, Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis, Free Radic Biol Med, 23, 419, 10.1016/S0891-5849(97)00101-9 · DOI
  39. Mason, 2006, Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism, J Biol Chem, 281, 9337, 10.1074/jbc.M513000200 · DOI · Paper page
  40. Self-Medlin, 2009, Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation, Biochim Biophys Acta, 1788, 1398, 10.1016/j.bbamem.2009.04.004 · DOI · Paper page
  41. Wratten, 1992, Structural and dynamic effects of oxidatively modified phospholipids in unsaturated lipid membranes, Biochemistry, 31, 10901, 10.1021/bi00159a034 · doi:10.1021/bi00159a034
  42. Sherratt, 2020, Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro, Biochimica et Biophysica Acta - Biomembranes, 1862
  43. Mason, 2015, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism, Biochimica et Biophysica Acta, 1848
  44. Jacob, 2013, Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein, J Cardiovasc Pharmacol, 62, 160, 10.1097/FJC.0b013e318294998d · DOI
  45. Aviram, 1998, Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation, Atherosclerosis, 138, 271, 10.1016/S0021-9150(98)00032-X · DOI · Paper page
  46. Mason, 2003, Membrane microdomains and vascular biology: emerging role in atherogenesis, Circulation, 107, 2270, 10.1161/01.CIR.0000062607.02451.B6 · DOI · Paper page
  47. Kellner-Weibel, 1999, Crystallization of free cholesterol in model macrophage foam cells, Arterioscler Thromb Vasc Biol, 19, 1891, 10.1161/01.ATV.19.8.1891 · DOI · Paper page
  48. Duewell, 2010, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature, 464, 1357, 10.1038/nature08938 · DOI · Paper page
  49. Amiya, 2013, Angiotensin II impairs endothelial nitric-oxide synthase bioavailability under free cholesterol-enriched conditions via intracellular free cholesterol-rich membrane microdomains, J Biol Chem, 288, 14497, 10.1074/jbc.M112.448522 · DOI
  50. Abela, 2006, Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events—a novel insight into plaque rupture by scanning electron microscopy, Scanning, 28, 1, 10.1002/sca.4950280101 · DOI
  51. Phillips, 2001, 7-Ketocholesterol forms crystalline domains in model membranes and murine aortic smooth muscle cells, Atherosclerosis, 159, 125, 10.1016/S0021-9150(01)00504-4 · DOI
  52. Abela, 2005, Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis, Clin Cardiol, 28, 413, 10.1002/clc.4960280906 · DOI
  53. Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis: An Official Journal of the American Heart Association, Inc. 1988;8:103-29. · DOI · Paper page
  54. Jakus, 2004, Advanced glycation end-products and the progress of diabetic vascular complications, Physiol Res, 53, 131, 10.33549/physiolres.930430 · DOI · Paper page
  55. Pennathur, 2007, Mechanisms for oxidative stress in diabetic cardiovascular disease, Antioxid Redox Signal, 9, 955, 10.1089/ars.2007.1595 · DOI · Paper page
  56. Pinel, 2016, EPA prevents fat mass expansion and metabolic disturbances in mice fed with a Western diet [S], Journal of Lipid Research, 57, 1382, 10.1194/jlr.M065458 · DOI
  57. Al Rijjal, 2021, Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function. iScience, 24
  58. Pal, 2020, Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner, The FASEB Journal, 34, 10640, 10.1096/fj.202000830R · DOI
  59. Bhatt, 2022, Icosapent ethyl reduces cardiovascular risk substantially and consistently regardless of waist circumference, Journal of the American College of Cardiology, 79, 1556, 10.1016/S0735-1097(22)02547-5 · doi:10.1016/s0735-1097(22)02547-5
  60. Tulenko, 1998, Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis, J Lipid Res, 39, 947, 10.1016/S0022-2275(20)33861-X · DOI · Paper page
  61. Paragh, 1999, Altered signal pathway in granulocytes from patients with hypercholesterolemia, Journal of Lipid Research, 40, 1728, 10.1016/S0022-2275(20)33420-9 · doi:10.1016/s0022-2275(20)33420-9
  62. Fang, 2006, Hypercholesterolemia Suppresses Inwardly Rectifying K+Channels in Aortic Endothelium In Vitro and In Vivo, Circulation Research, 98, 1064, 10.1161/01.RES.0000218776.87842.43 · DOI · Paper page
  63. Ruocco, 1984, Interaction of cholesterol with galactocerebroside and galactocerebroside-phosphatidylcholine bilayer membranes, Biophys J, 46, 695, 10.1016/S0006-3495(84)84068-0 · DOI
  64. Mason, 1992, Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer, Mol Pharmacol, 41, 315, 10.1016/S0026-895X(25)08879-0 · DOI · Paper page
  65. Stary, 1995, A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis, Circulation, 92, 1355, 10.1161/01.CIR.92.5.1355 · DOI · Paper page
  66. Falk, 2006, Pathogenesis of Atherosclerosis, Journal of the American College of Cardiology, 47, C7, 10.1016/j.jacc.2005.09.068 · DOI · Paper page
  67. Virmani, 2000, Lessons From Sudden Coronary Death, Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1262, 10.1161/01.ATV.20.5.1262 · DOI · Paper page
  68. Erdmann, 2013, Dysfunctional nitric oxide signalling increases risk of myocardial infarction, Nature, 504, 432, 10.1038/nature12722 · DOI · Paper page
  69. Emdin, 2018, Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling, Circulation, 137, 222, 10.1161/CIRCULATIONAHA.117.028021 · DOI · Paper page
  70. De Caterina, 1994, The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells, Arterioscler Thromb, 14, 1829, 10.1161/01.ATV.14.11.1829 · DOI · Paper page
  71. Weber, 1995, Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha, Arterioscler Thromb Vasc Biol, 15, 622, 10.1161/01.ATV.15.5.622 · DOI · Paper page
  72. Haiden, 2012, Effect of eicosapentaenoic acid on regional arterial stiffness: Assessment by tissue Doppler imaging, World J Cardiol, 4, 256, 10.4330/wjc.v4.i8.256 · DOI
  73. Ito, 2014, An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia, J Atheroscler Thromb, 21, 248, 10.5551/jat.19976 · DOI
  74. Takaki, 2011, Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study, J Atheroscler Thromb, 18, 857, 10.5551/jat.7260 · DOI · Paper page
  75. Mita, 2007, Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes, Atherosclerosis, 191, 162, 10.1016/j.atherosclerosis.2006.03.005 · DOI
  76. Li, 2007, Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase, Biochimie, 89, 169, 10.1016/j.biochi.2006.10.009 · DOI
  77. Mason, 2018, Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin, Biomedicine & Pharmacotherapy, 103, 1231, 10.1016/j.biopha.2018.04.118 · DOI · Paper page
  78. Hou, 2016, Omega-3 fatty acids, lipid rafts, and T cell signaling, Eur J Pharmacol, 785, 2, 10.1016/j.ejphar.2015.03.091 · DOI · Paper page
  79. Lee, 2015, Effects of eicosapentaenoic acid on the cytoprotection through Nrf2-mediated heme oxygenase-1 in human endothelial cells, Journal of Cardiovascular Pharmacology, 66, 108, 10.1097/FJC.0000000000000251 · DOI
  80. Zhang, 2017, Quantitative proteomics reveals key proteins regulated by eicosapentaenoic acid in endothelial activation, Biochemical and Biophysical Research Communications, 487, 464, 10.1016/j.bbrc.2017.04.091 · DOI
  81. Fredenburgh, 2015, Haeme oxygenase signalling pathway: implications for cardiovascular disease, European Heart Journal, 36, 1512, 10.1093/eurheartj/ehv114 · DOI
  82. Duckers, 2001, Heme oxygenase-1 protects against vascular constriction and proliferation, Nature Medicine, 7, 693, 10.1038/89068 · DOI · Paper page
  83. Otterbein, 2003, Heme oxygenase-1: unleashing the protective properties of heme, Trends in Immunology, 24, 449, 10.1016/S1471-4906(03)00181-9 · DOI · Paper page
  84. Luo, 2018, Heme oxygenase-1 ameliorates oxidative stress-induced endothelial senescence via regulating endothelial nitric oxide synthase activation and coupling, Aging (Albany NY), 10, 1722, 10.18632/aging.101506 · DOI
  85. Polte, 2000, Heme Oxygenase-1 Is a cGMP-Inducible Endothelial Protein and Mediates the Cytoprotective Action of Nitric Oxide, Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1209, 10.1161/01.ATV.20.5.1209 · DOI · Paper page
  86. Choi, 2003, Nitric oxide priming protects nitric oxide-mediated apoptosis via heme oxygenase-1 induction, Free Radic Biol Med, 34, 1136, 10.1016/S0891-5849(03)00064-9 · DOI
  87. Soares, 2004, Heme Oxygenase-1 Modulates the Expression of Adhesion Molecules Associated with Endothelial Cell Activation, The Journal of Immunology, 172, 3553, 10.4049/jimmunol.172.6.3553 · DOI · Paper page
  88. Ishikawa, 2001, Heme Oxygenase-1 Inhibits Atherosclerotic Lesion Formation in LDL-Receptor Knockout Mice, Circulation Research, 88, 506, 10.1161/01.RES.88.5.506 · DOI · Paper page
  89. Ignarro, 1987, Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide, Proc Natl Acad Sci USA., 84, 9265, 10.1073/pnas.84.24.9265 · DOI · Paper page
  90. Ignarro, 2002, Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide, Circ Res, 90, 21, 10.1161/hh0102.102330 · DOI · Paper page
  91. Anderson, 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, N Engl J Med, 332, 488, 10.1056/NEJM199502233320802 · DOI · Paper page
  92. Mason, 2005, Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans, Circulation, 112, 3795, 10.1161/CIRCULATIONAHA.105.556233 · DOI · Paper page
  93. Paniagua, 2001, Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature: diminished activity in hypertensive and hypercholesterolemic patients, Circulation, 103, 1752, 10.1161/01.CIR.103.13.1752 · DOI · Paper page
  94. Nishizaki, 2014, Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome, Am J Cardiol, 113, 441, 10.1016/j.amjcard.2013.10.011 · DOI
  95. Panza, 1990, Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension, N Engl J Med, 323, 22, 10.1056/NEJM199007053230105 · DOI · Paper page
  96. Huk, 1997, L-Arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle, Circulation, 96, 667, 10.1161/01.CIR.96.2.667 · DOI · Paper page
  97. Dawoud, 2018, A nanomedical approach to understanding the mechanism of endothelial function and dysfunction – clinical implications, J Nanomed, 2, 1006
  98. Malinski, 2005, Understanding nitric oxide physiology in the heart: a nanomedical approach, Am J Cardiol, 96, 10.1016/j.amjcard.2005.07.029 · DOI
  99. Sherratt, 2021, Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability, Prostaglandins Leukot Essent Fatty Acids, 173
  100. Drouin, 2019, The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family, Biochimie, 159, 36, 10.1016/j.biochi.2019.01.022 · DOI · Paper page
  101. Dakroub, 2021, Eicosapentaenoic acid membrane incorporation stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages, Biochim Biophys Acta Mol Cell Biol Lipids, 1866
  102. Singh, 2022, Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT, Journal of the American College of Cardiology, 79, 220, 10.1016/j.jacc.2021.11.005 · DOI
  103. O'Connell, 2020, Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites, Eur Heart J Suppl, 22
  104. Shearer, 2009, Impact of circulating esterified eicosanoids and other oxylipins on endothelial function, Current Atherosclerosis Reports, 11, 403, 10.1007/s11883-009-0061-3 · DOI
  105. Bonafini, 2017, Omega-3 fatty acids and cytochrome P450-derived eicosanoids in cardiovascular diseases: Which actions and interactions modulate hemodynamics?, Prostaglandins & Other Lipid Mediators, 34, 10.1016/j.prostaglandins.2017.01.004 · DOI
  106. Hansen, 2019, The protectin family of specialized pro-resolving mediators: potent immunoresolvents enabling innovative approaches to target obesity and diabetes, Frontiers in Pharmacology, 9, 10.3389/fphar.2018.01582 · DOI
  107. Mitchell, 2019, Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system, Br J Pharmacol, 176, 1038, 10.1111/bph.14167 · DOI · Paper page
  108. Braeckman, 2013, Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study), Prostaglandins, Leukotrienes, and Essential Fatty Acids, 89, 195, 10.1016/j.plefa.2013.07.005 · DOI
  109. Larsson, 2004, Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms, Am J Clin Nutr, 79, 935, 10.1093/ajcn/79.6.935 · DOI · Paper page
  110. Gabbs, 2015, Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs, Advances in Nutrition, 6, 513, 10.3945/an.114.007732 · DOI · Paper page
  111. Djuricic, 2021, Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021, Nutrients, 13, 2421, 10.3390/nu13072421 · DOI · Paper page
  112. Fredman, 2017, Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy, Am J Pathol, 187, 1211, 10.1016/j.ajpath.2017.01.018 · DOI · Paper page
  113. Yamada, 2017, Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice, Nutr Metab, 14, 33, 10.1186/s12986-017-0188-0 · DOI
  114. Chiurchiù, 2019, Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes, The FASEB Journal, 33, 909, 10.1096/fj.201801017R · DOI
  115. Zhang, 2005, Dietary (n-3) polyunsaturated fatty acids modulate murine Th1/Th2 balance toward the Th2 pole by suppression of Th1 development, J Nutr, 135, 1745, 10.1093/jn/135.7.1745 · DOI
  116. Monk, 2012, Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis, PLoS One, 7, e49739, 10.1371/journal.pone.0049739 · DOI · Paper page
  117. Monk, 2013, n3 PUFAs reduce mouse CD4+ T-cell ex vivo polarization into Th17 cells, J Nutr, 143, 1501, 10.3945/jn.113.178178 · DOI
  118. Chiurchiu, 2016, Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses, Sci Transl Med, 8, 10.1126/scitranslmed.aaf7483 · DOI · Paper page
  119. Oner, 2021, Resolvin E1 Regulates Th17 Function and T Cell Activation, Frontiers in Immunology, 12
  120. Nosaka, 2017, Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study, International Journal of Cardiology, 228, 173, 10.1016/j.ijcard.2016.11.105 · DOI · Paper page
  121. Verma, 2021, Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG, Circulation, 144, 1845, 10.1161/CIRCULATIONAHA.121.056290 · DOI · Paper page
  122. Peterson, 2022, Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention- insights from REDUCE-IT PCI, Journal of the American Heart Association, 11, 10.1161/JAHA.121.022937 · DOI · Paper page
  123. 2022, Coronavirus (COVID-19) Dashboard, World Health Organization
  124. Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, The Lancet, 1
  125. Ambrosy, 2021, Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE), Am Heart J, 235, 54, 10.1016/j.ahj.2021.01.018 · DOI
  126. Mason, 2021, Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction, The American Journal of Medicine, 134, 1085, 10.1016/j.amjmed.2021.03.014 · DOI · Paper page
  127. Sherratt, 2018, Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid, Biochemical and Biophysical Research Communications, 496
  128. Pisaniello, 2021, Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects, Atherosclerosis, 324, 27, 10.1016/j.atherosclerosis.2021.03.003 · DOI
  129. Libby, 2020, COVID-19 is, in the end, an endothelial disease, European Heart Journal, 41, 3038, 10.1093/eurheartj/ehaa623 · DOI · Paper page
  130. Teuwen, 2020, COVD-19: the vasculature unleashed, Nature Reviews Immunology, 20, 389, 10.1038/s41577-020-0343-0 · DOI · Paper page
  131. Kurahara, 2020, Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn, Journal of Molecular and Cellular Cardiology, 148, 50, 10.1016/j.yjmcc.2020.08.013 · DOI
  132. Liu, 2014, Eicosapentaenoic acid attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling, Frontiers in Physiology, 5, 10.3389/fphys.2014.00440 · DOI
  133. Lemoine, 2020, Relationship between Omega-3 and Omega-6 Fatty Acid Intake and Chronic Obstructive Pulmonary Disease Morbidity, Annals of the American Thoracic Society, 17, 378, 10.1513/AnnalsATS.201910-740RL · DOI

Cited by

Metadata

Authors
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P.
Venue
Prostaglandins, Leukotrienes and Essential Fatty Acids
Publisher
Elsevier BV
Published
2022-07
Volume
182
Pages
102450
ISSN
0952-3278
Cited by
43
References
46
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.